Breakthrough Medicines for Cancer, Chronic Inflammation & Fibrosis

| FDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for...

| Tvardi Therapeutics to Present at the Morgan Stanley 20th Annual Global...

| Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for Idiopathic..

Tvardi Therapeutics is a private, clinical stage biotechnology company developing a new class of breakthrough medicines for diverse cancers and chronic inflammatory and fibrotic diseases. Tvardi is focused on the development of orally delivered, small molecule inhibitors of STAT3, a key signaling molecule positioned at the intersection of many disease pathways.

Tvardi Therapeutics TTI-101

Science

Developing novel inhibitors of STAT3, a molecule implicated in the initiation and progression of cancer and fibrosis.

Team

Tvardi Therapeutics is led by a group of experienced entrepreneurs, innovative scientists & dedicated physicians.

Tvardi Named 2021 Winner of Fierce 15 Biotech

Fierce Biotech has named Tvardi Therapeutics as one of 2021’s Fierce 15 biotechnology companies, designating it as one of the most promising biotechnology companies in the industry.

We use cookies to ensure that we give you the best experience on our website. By using this website you agree to the Privacy Policy and  Terms of Use.